Healthcare / BiotechnologyCanadian Sec
$0.41
-0.03 (-5.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-248443.00 · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$11M
P/E
N/A
•EV/EBITDA
N/A
•ROE
516.1%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-423765.0 · FCF $-248443.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Net Income | $-423765.00 | $-423765.00 | — |
| EBITDA | $-423765.00 | $-423765.00 | — |
| EPS | -0.02 | -0.02 | — |
| Balance Sheet | |||
| Debt/Equity | — | — | -7.06 |
| Current Ratio | 13.33 | 13.33 | — |
| Cash Flow | |||
| Free Cash Flow | $-248443.00 | $-248443.00 | — |
| Returns | |||
| ROE | 516.1% | 516.1% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-66.8%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → -0.02
Residual
-66.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.